Allspring Global Investments Holdings LLC Grows Position in IQVIA Holdings Inc. $IQV

Allspring Global Investments Holdings LLC boosted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 486.2% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 48,376 shares of the medical research company’s stock after acquiring an additional 40,124 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in IQVIA were worth $8,340,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in IQV. Brighton Jones LLC raised its position in IQVIA by 244.4% in the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after purchasing an additional 2,537 shares during the period. Empowered Funds LLC grew its stake in shares of IQVIA by 102.1% in the first quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock valued at $1,715,000 after buying an additional 4,915 shares in the last quarter. Sivia Capital Partners LLC purchased a new stake in IQVIA during the second quarter worth about $514,000. First Trust Advisors LP boosted its holdings in IQVIA by 14.8% in the second quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company’s stock valued at $14,501,000 after purchasing an additional 11,845 shares during the period. Finally, NewEdge Advisors LLC raised its stake in IQVIA by 5.4% during the 2nd quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company’s stock worth $3,582,000 after acquiring an additional 1,155 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on IQV shares. Morgan Stanley reissued an “equal weight” rating and set a $200.00 target price (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. Robert W. Baird lifted their price objective on IQVIA from $230.00 to $249.00 and gave the company an “outperform” rating in a research note on Wednesday, July 1st. Weiss Ratings upgraded shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, July 15th. Deutsche Bank Aktiengesellschaft set a $240.00 price target on shares of IQVIA in a report on Thursday, July 9th. Finally, Wall Street Zen lowered IQVIA from a “buy” rating to a “hold” rating in a report on Saturday, June 27th. Thirteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, IQVIA has an average rating of “Moderate Buy” and a consensus target price of $225.71.

IQVIA Stock Down 1.3%

IQVIA stock opened at $198.96 on Thursday. IQVIA Holdings Inc. has a twelve month low of $154.50 and a twelve month high of $247.04. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75. The firm has a market cap of $33.21 billion, a PE ratio of 24.65, a P/E/G ratio of 1.81 and a beta of 1.20. The firm’s 50 day moving average price is $186.73 and its two-hundred day moving average price is $187.36.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The business had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. During the same period in the previous year, the company posted $2.70 EPS. IQVIA’s revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, research analysts predict that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA declared that its Board of Directors has approved a stock buyback program on Thursday, May 7th that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s leadership believes its stock is undervalued.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.